Study Phase 2

A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm

Trial Information

Generic NameCanagliflozinProduct NameINVOKANA®Therapeutic AreaNutritional and Metabolic DiseasesEnrollment451% Female48%% White73%
Product ClassDiabetes Related- OtherSponsor Protocol Number28431754DIA2001Data PartnerJohnson & JohnsonCondition StudiedDiabetes Mellitus, Type 2Mean/Median Age (Years)54

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.